Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avycaz PK/PD in Critically Ill Patients
NCT02822950Phase 1Completed
- Sponsor
- Michigan State University
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 1, open-label, single-arm trial of ceftazidime + avibactam in skin and soft tissue infection (SSTI), urinary tract infection (UTI), Intra-abdominal infection (IAI) and 1 more, sponsored by Michigan State University. Primary endpoints: Volume of Distribution at 8 hours, Pharmacokinetic Half Life at 8 hours and 3 more. Started Jan 2017; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
skin and soft tissue infection (SSTI)urinary tract infection (UTI)Intra-abdominal infection (IAI)pneumonia
Beyond the preview
Go deeper on NCT02822950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02822950.